Myocardial Characterization for Early Diagnosis, Treatment Response Monitoring, and Risk Assessment in Systemic Light-Chain Amyloidosis
Olivier F. Clerc,Sarah A. M. Cuddy,Michael Jerosch-Herold,Dominik C Benz,Ethan Katznelson,Jocelyn Canseco Neri,Alexandra Taylor,Marie Foley Kijewski,Giada Bianchi,Frederick L. Ruberg,Marcelo F. Di Carli,Ronglih Liao,Raymond Y. Kwong,Rodney H. Falk,Sharmila Dorbala,Clerc,O. F.,Cuddy,S. A.,Jerosch-Herold,M.,Benz,D. C.,Katznelson,E.,Canseco Neri,J.,Taylor,A.,Kijewski,M. F.,Bianchi,G.,Ruberg,F. L.,Di Carli,M. F.,Liao,R.,Kwong,R. Y.,Falk,R. H.,Dorbala,S.
DOI: https://doi.org/10.1101/2023.10.04.23296572
2023-10-06
MedRxiv
Abstract:Aims: In systemic light-chain (AL) amyloidosis, cardiac involvement portends poor prognosis. Using myocardial characteristics on magnetic resonance imaging (MRI), this study aimed to detect early myocardial alterations, to analyze temporal changes with plasma cell therapy, and to predict risk of major adverse cardiac events (MACE) in AL amyloidosis. Methods and Results: Participants with recently diagnosed AL amyloidosis were prospectively enrolled. Presence of AL cardiomyopathy (AL-CMP vs. AL-non-CMP) was determined by abnormal cardiac biomarkers. MRI was performed at baseline and 6 months, with 12-month imaging in AL-CMP cohort. MACE was defined as all-cause death, heart failure hospitalization, or cardiac transplantation. Mayo AL stage was based on troponin T, NT-proBNP, and difference in free light chains. The study cohort included 80 participants (median age 62 years, 58% males). Median left ventricular extracellular volume (ECV) was significantly higher in AL-CMP (53% vs. 30%, p 32%) in all AL-CMP and in 47% of AL-non-CMP. ECV tended to increase at 6 months and decreased significantly from 6 to 12 months in AL-CMP (median -3%, p=0.011). ECV was strongly associated with MACE (p 48% identified a cohort with 74% MACE. Conclusions: In AL amyloidosis, ECV detects subclinical cardiomyopathy. ECV tends to increase from baseline to 6 months and decreases significantly from 6 and 12 months of plasma cell therapy in AL-CMP. ECV provides excellent risk stratification and offers additional prognostic performance over Mayo AL stage.